IGC news

Latest 3 stories · newest Jul 13, 2026

IGC

IGC Pharma presents illustrative valuations for Alzheimer's treatment IGC-AD1

IGC Pharma disclosed a presentation detailing potential stock value scenarios for Alzheimer's drug IGC-AD1. The company anticipates potential valuations ranging from $300 million to $4 billion contingent upon successful clinical development and regulatory milestones.

Other Jul 13, 2026 sentiment 0.00 SEC filing ↗

IGC

IGC Pharma enters agreement to sell shares at $0.27 per share

IGC Pharma entered into a Stock Purchase Agreement to issue shares to a Purchaser for $0.27 per share. The transaction is scheduled to close on June 30, 2026, and will be settled through the cancellation of existing debt.

Offering Jul 6, 2026 sentiment +0.10 SEC filing ↗

IGC

IGC Pharma files exhibit document with SEC

IGC Pharma submitted an exhibit filing to the SEC. The document lacks substantive business information for market analysis.

Other Jun 8, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same IGC feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/IGC/newsSTART FREE